<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182154</url>
  </required_header>
  <id_info>
    <org_study_id>1199.20</org_study_id>
    <nct_id>NCT02182154</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers</brief_title>
  <official_title>Metabolism and Pharmacokinetics of [14C]-BIBF 1120 After Administration of Single Doses of 100 mg [14C]-BIBF 1120 Oral Solution in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the metabolic profile,

      to obtain the mass balance after oral administration,

      to determine the concentration of [14C]-radioactivity in blood cells, plasma, urine and
      faeces,

      to determine BIBF 1120 and BIBF 1202 concentrations in plasma, urine, and faeces, if
      feasible,

      to determine the protein binding of [14C]-radioactivity,

      to determine the pharmacokinetics of BIBF 1120, BIBF 1202 and total radioactivity after a
      single oral administration of [14C]-BIBF 1120 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[14C]-radioactivity in plasma and whole blood (C Blood cells/C plasma ratio of [14C]-radioactivity)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[14C]-radioactivity in urine</measure>
    <time_frame>Up to 120 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the plasma protein binding of total [14C]-radioactivity in human plasma samples ex vivo</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration-time profiles of total radioactivity in whole blood and plasma</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[14C]-metabolic profile and identification of metabolites in urine, in comparison with various animal species</measure>
    <time_frame>Up to 120 h after drug aministration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[14C]-radioactivity in faeces</measure>
    <time_frame>up to 120 h after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[14C]-metabolic profile and identification of metabolites in faeces, in comparison with various animal species</measure>
    <time_frame>Up to 120 h after drug aministration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>[14C]-metabolic profile and identification of metabolites in plasma, in comparison with various animal species</measure>
    <time_frame>Up to 96 h after drug aministration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from dosing to peak concentration (tmax)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma from zero time to 24 hours (AUC0-24)</measure>
    <time_frame>Up to 24 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma from zero time to the time of the last quantifiable drug concentration (AUC0-tz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma from zero time to infinity (AUC0-∞)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time of the analyte molecules in the body after oral administration (MRTpo)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total clearance of the analyte in plasma following extravascular administration (CL/F)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of analyte eliminated in urine from 0 to the limit of the last quantifiable data point (fe0-tz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of analyte eliminated in faeces from 0 to the limit of the last quantifiable data point (fe faeces,0-tz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analyte that was eliminated in faeces from 0 to the limit of the last quantifiable data point (Ae faeces,0-tz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analyte that was eliminated in urine from 0 to the limit of the last quantifiable data point (Ae0-tz)</measure>
    <time_frame>Up to 96 h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Baseline, day 14 after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in routine laboratory</measure>
    <time_frame>Baseline, day 14 after drug aministration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to day 14 after drug aministration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram</measure>
    <time_frame>Baseline, day 14 after drug aministration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator according a 4 point scale</measure>
    <time_frame>Day 14 after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBF 1120 ES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120 ES</intervention_name>
    <arm_group_label>BIBF 1120 ES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects as determined by results of screening

          2. Signed written informed consent in accordance with GCP and local legislation

          3. Age ≥21 and ≤55 years

          4. Body Mass Index ≥18.5 kg/m2 and ≤29.9 kg/m2

        Exclusion Criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          2. History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          3. History of any major surgery within the last four weeks before participation in this
             study or any bone fracture within the last two months

          4. History of orthostatic hypotension, fainting spells and blackouts

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          6. Chronic or relevant acute infections

          7. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          8. History of any bleeding disorder including prolonged or habitual bleeding, other
             haematologic disease or cerebral bleeding (e.g. after a car accident) or commotio
             cerebri

          9. Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

         10. Planned use of any drugs which might influence the results of the trial within 10 days
             prior to administration or during the trial

         11. Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

         12. Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

         13. Alcohol abuse (&gt; 60 g/day)

         14. Drug abuse

         15. Blood donation within 1 month prior to administration or during the trial

         16. Excessive physical activities within 5 days prior to administration or during the
             trial

         17. Any laboratory value outside the reference range, unless considered to lack clinical
             reference

         18. Female gender

         19. Male subjects must agree to minimize the risk of female partners becoming pregnant
             from the dosing day until 3 months after the completion of the study. Acceptable
             methods of contraception for male volunteers include a vasectomy no less than 3 months
             prior to dosing, barrier contraception or a medically accepted contraceptive method.
             For female partners of male volunteers, acceptable methods of contraception include
             intra-uterine device, tubal ligation, hormonal contraceptive since at least two months
             and diaphragm with spermicide
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

